Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
AstraZeneca, the British drugmaker working on a few of the world’s leading COVID-19 vaccine candidates, conquer third-quarter sales estimates on Thursday and revealed it expects data from late-stage trials of the vaccine later this year.
The business has taken on the evolution of Oxford University’s potential COVID-19 vaccine, scoring billions in financing and signing multiple prices to supply over three billion doses to countries around the world.
Data in October showed the vaccine, known as AZD1222 or ChAdOx1 nCoV-19, produces an immune response in both old and young adults. AstraZeneca is expected to publish eagerly awaited late-stage clinical trial data in the coming weeks.
Expectations are that Britain could start rolling out a successful vaccine in late December or early 2021.
While AstraZeneca marches on with the vaccine, demand for its diverse portfolio of drugs remained strong despite disruptions to health systems because of the pandemic.
Product sales, which exclude payments from collaborations, climbed 7% to $6.52 billion for the three months ended Sept. 30 on a constant-currency basis, before a company-compiled consensus of $6.50 billion.
However, the business reported core earnings of 94 cents per share, lower than analysts’ expectations of 98 cents.
AstraZeneca said it expects total revenue to increase by a high single-digit to a reduced double-digit percent and core earnings per share to increase by a mid- to high-teens percentage.
Australia orders more COVID-19 vaccines for total of 135 million doses The Australian government has agreed to purchase two COVID-19 vaccines in development, beefing up the nation’s prospective arsenal against the pandemic to 135 million doses since it aims to complete a mass inoculation programme within months.
Prime Minister Scott Morrison said on Thursday the government will purchase 40 million vaccine doses from Novavax, and 10 million in Pfizer and BioNTech.
That adds to the 85 million doses Australia has already committed to buy from AstraZeneca and CSL Ltd should trials prove successful, taking the nation’s total anticipated outlay to A$3.2 billion ($2.3 billion).
“We aren’t putting all our eggs in one basket,” Morrison told reporters in Sydney.
Health Minister Greg Hunt said the Novavax and Pfizer-BioNTech vaccines, which is manufacturd in the USA and Europe, would match the AstraZeneca and CSL products, which would be manufactured in Australia.
“That means we’re now in a really strong position with the portfolio of four unique vaccines, two protein, one viral vector and one MRMA, that is the Pfizer vaccine, and that’s innovative – the world has not had an MRMA vaccine before,” Hunt told TV broadcaster Nine Network.
The Pfizer-BioNTech, AstraZeneca and Novavax vaccines are regarded as among the leading candidates in the international race to get regulatory approval.
Should trials prove successful, Australia expects to receive the first batches of the AstraZeneca vaccine in early 2021 and begin a mass rollout in March to be completed by the end of the year.
Follow our whole coverage of the coronavirus pandemic here.
If all four vaccines come to market, Australia and its population of 26 million people will find itself with excess doses, even allowing for the fact that several of the candidates in development require two doses to work.
Australia has said it intends to donate any surplus doses to Pacific Island nations and has committed to spending around A$525 million to ensure Pacific nations and East Timor achieve whole immunisation coverage.
Australia is the biggest aid donor to the Pacific islands and has sought in recent months to step up its involvement from concern it risks being overshadowed by Chinese aid and financial support.
The announcement of the new planned vaccine purchases came as Australia recorded no cases of locally sent COVID-19 over the past 24 hours for the second time in a week. The country on Sunday recorded the first day with no regional cases since early June.
Australia has reported just over 27,600 coronavirus instances and 907 deaths, far fewer than most other developed countries because of extensive testing, contact tracing and lockdowns.
As federal case numbers have slowed slowed to fewer than 10 daily, states and territories have been reopening boundaries and relaxing differing levels of social distancing restrictions.
Qantas Airways on Thursday said it would boost the amount of flights between between New South Wales and Victoria states after officials announced on Wednesday that border restrictions would be lifted later this month.
The national carrier will go from the ten return flights it’s currently operating each week between Sydney and Melbourne to over 250 flights between the two countries weekly. The Sydney-Melbourne route was among the busiest in the world ahead of the pandemic.
